Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg /
day) reduces the risk of cardiovascular disease in patients with chronic kidney disease
(stage 3 or 4).
Phase:
Phase 3
Details
Lead Sponsor:
Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales